Ajovy (fremanezumab-vfrm) / Teva 
Welcome,         Profile    Billing    Logout  
 7 Diseases   13 Trials   13 Trials   1459 News 


«12...567891011121314151617»
  • ||||||||||  Journal:  Migraine overview and summary of current and emerging treatment options. (Pubmed Central) -  Jul 5, 2020   
    The newly approved CGRP antagonists are erenumab, fremanezumab, and galcanezumab, while eptinezumab looks to 2020 for approval. Lasmiditan, ubrogepant, and rimegepant are currently emerging acute migraine therapies that may be added to the arsenal of current migraine management.
  • ||||||||||  TEV-48125 / Teva, Ajovy (fremanezumab) / Otsuka, Teva
    Journal:  CSD-induced arterial dilatation and plasma protein extravasation are unaffected by fremanezumab: implications for CGRP's role in migraine with aura. (Pubmed Central) -  Jun 19, 2020   
    It sharpens the need to accept the view that there is more than one truth to migraine pathophysiology and that it is unlikely that one theory will explain all types of migraine headache or the mechanisms of action of drugs that prevent it. Regarding the latter, it is concluded that not all vascular responses in the meninges are born alike and consequently, that drugs that prevent vascular dilatation through different molecular pathways may have different therapeutic outcomes in different types of migraine.
  • ||||||||||  Journal:  What's New in the Treatment of Migraine. (Pubmed Central) -  Jun 18, 2020   
    Many new and exciting therapies exist for the treatment of migraine. Keeping up with this rapidly evolving field is important in reducing disability from the common disease of migraine.
  • ||||||||||  Ajovy (fremanezumab) / Otsuka, Teva
    Enrollment open, Trial completion date, Trial primary completion date:  A Study to Test the Effectiveness and Safety of Fremanezumab on Patients With Fibromyalgia (clinicaltrials.gov) -  Jun 4, 2020   
    P2,  N=240, Recruiting, 
    The purpose of this review is to evaluate the seven CGRP antagonists and their future place in therapy. Active, not recruiting --> Recruiting | Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2021 --> Aug 2022
  • ||||||||||  Journal:  CGRP, Amylin, Immunology, and Headache Medicine. (Pubmed Central) -  May 29, 2020   
    To better understand potential immunogenic risks and off-target toxicities of the anti-CGRP monoclonal antibodies, this review discusses immunology and CGRP and reviews IgG structure and function, monoclonal antibody production, ligand-antigen-antibody relationships, and clinical CGRP mAb specifics. Upon completion, the reader should better summarize CGRP antagonist fundamentals, recall antibody structure and function, restate therapeutic mAbs attributes, and appraise immunogenic risks.
  • ||||||||||  Journal:  Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. (Pubmed Central) -  May 22, 2020   
    Gepants are a safe alternative to triptans for the acute management of migraine and are currently being tested for prevention, thus representing the first transitional molecules for disease therapy. In the future, it might be possible to adapt the treatment according to patients' characteristics and disease phenotype even combining the two treatments targeting the CGRP pathway.
  • ||||||||||  Ajovy (fremanezumab) / Otsuka, Teva
    Enrollment closed:  A Study to Test the Effectiveness and Safety of Fremanezumab on Patients With Fibromyalgia (clinicaltrials.gov) -  May 6, 2020   
    P2,  N=240, Active, not recruiting, 
    In the future, it might be possible to adapt the treatment according to patients' characteristics and disease phenotype even combining the two treatments targeting the CGRP pathway. Recruiting --> Active, not recruiting
  • ||||||||||  TEV-48125 / Teva, Ajovy (fremanezumab) / Otsuka, Teva
    Review, Journal:  Fremanezumab for migraine. (Pubmed Central) -  Apr 30, 2020   
    Sponsorship: This research was funded internally by Conduent, Richmond, VA. No abstract available
  • ||||||||||  Ajovy (fremanezumab) / Otsuka, Teva
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH) (clinicaltrials.gov) -  Apr 28, 2020   
    P2,  N=87, Active, not recruiting, 
    No abstract available Recruiting --> Active, not recruiting | N=172 --> 87 | Trial completion date: Jan 2021 --> Jun 2020 | Trial primary completion date: Oct 2020 --> Mar 2020
  • ||||||||||  Journal:  Monoclonal antibodies for the prevention of migraine. (Pubmed Central) -  Apr 23, 2020   
    mAbs are also effective in patients with medication overuse and with comorbid depression or anxiety disorders. Taken together, mAbs are likely to usher in a new era in migraine prevention and provide significant value to patients.
  • ||||||||||  TEV-48125 / Teva, Ajovy (fremanezumab) / Otsuka, Teva
    Journal:  Fremanezumab for the preventive treatment of migraine. (Pubmed Central) -  Apr 22, 2020   
    Fremanezumab has a favorable efficacy and safety profile, which is maintained over the long term. Data from patient subgroups with more-complex disease are promising, and an ongoing study in treatment-refractory patients is evaluating the efficacy of fremanezumab in patients who have failed on multiple prior therapies.
  • ||||||||||  TEV-48125 / Teva, Ajovy (fremanezumab) / Otsuka, Teva
    [VIRTUAL] Pooled Analysis of Cardiovascular Safety With Fremanezumab Treatment in Patients With Migraine and Concomitant Triptan Use (Main Auditorium) -  Apr 9, 2020 - Abstract #EAN2020EAN_1582;    
    This pooled analysis demonstrates that both fremanezumab treatment regimens over 12 weeks improved HRQoL, productivity, and satisfaction, as measured by MSQoL, WPAI, and PGIC, respectively, in patients ≥60 years of age with EM or CM. This pooled analysis demonstrates that fremanezumab treatment over 12 weeks was well tolerated in patients with migraine and concomitant triptan use, with similar CV tolerability to those with no triptan use.